Vasopressin Use in the Support of Organ Donors: Physiological Rationale and Review of the Literature
- PMID: 37101535
- PMCID: PMC10125506
- DOI: 10.1097/CCE.0000000000000907
Vasopressin Use in the Support of Organ Donors: Physiological Rationale and Review of the Literature
Abstract
The objective of this review was to depict the physiological and clinical rationale for the use of vasopressin in hemodynamic support of organ donors. After summarizing the physiological, pharmacological concepts and preclinical findings, regarding vasopressin's pathophysiological impacts, we will present the available clinical data.
Data sources: Detailed search strategies in PubMed, OVID Medline, and EMBASE were undertaken using Medical Subject Headings and Key Words.
Study selection: Physiological articles regarding brain death, and preclinical animal and human studies about the use of vasopressin or analogs, as an intervention in organ support for donation, were considered.
Data extraction: Two authors independently screened titles, abstracts, and full text of articles to determine eligibility. Data encompassing models, population, methodology, outcomes, and relevant concepts were extracted.
Data synthesis: Following brain death, profound reduction in sympathetic outflow is associated with reduced cardiac output, vascular tone, and hemodynamic instability in donors. In addition to reducing catecholamine needs and reversing diabetes insipidus, vasopressin has been shown to limit pulmonary injury and decrease systemic inflammatory response in animals. Several observational studies show the benefit of vasopressin on hemodynamic parameters and catecholamine sparing in donors. Small trials suggest that vasopressin increase organ procurement and have some survival benefit for recipients. However, the risk of bias is overall concerning, and therefore the quality of the evidence is deemed low.
Conclusions: Despite potential impact on graft outcome and a protective effect through catecholamine support sparing, the benefit of vasopressin use in organ donors is based on low evidence. Well-designed observational and randomized controlled trials are warranted.
Keywords: catecholamines; hemodynamic support; organ donation; organ procurement; vasopressin.
Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Conflict of interest statement
The authors have disclosed that they do not have any potential conflicts of interest.
Figures
References
-
- Frenette AJ, Charbonney E, D’Aragon F, et al. ; Canadian Critical Care TrialsGroup: A Canadian survey of critical care physicians’ hemodynamic management of deceased organ donors. Can J Anaesth 2019; 66:1162–1172 - PubMed
-
- Frenette AJ, Williamson D, Weiss MJ, et al. : Worldwide management of donors after neurological death: A systematic review and narrative synthesis of guidelines. Can J Anaesth 2020; 67:1839–1857 - PubMed
-
- Treschan TA, Peters J: The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006; 105:599–612; quiz 639–640 - PubMed
-
- Smith M: Physiologic changes during brain stem death—lessons for management of the organ donor. J Heart Lung Transplant 2004; 23(9 Suppl):S217–S222 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
